Ultragenyx Pharma (RARE) – Major News
-
Ultragenyx Pharma (RARE) Tops Q4 EPS by 18c
-
Ultragenyx Pharma (RARE) Misses Q3 EPS by 16c
-
Ultragenyx Pharma (RARE) Misses Q2 EPS by 16c, beats revenue
-
Ultragenyx Pharma (RARE) Misses Q4 EPS by 2c
-
Ultragenyx Pharma (RARE) Misses Q2 EPS by 51c; Reaffirms Product Revenue Guidance
-
Ultragenyx Pharma (RARE) Misses Q1 EPS by 43c
-
Ultragenyx Pharma (RARE) Misses Q4 EPS by 45c
-
Ultragenyx Pharma (RARE) Tops Q3 EPS by 33c
-
Ultragenyx Pharma (RARE) Misses Q2 EPS by 45c, Revenues Beat
-
Ultragenyx Pharma (RARE) Misses Q1 EPS by 79c, Revenues Beat
-
Ultragenyx Pharma (RARE) Reports Q4 Loss of $0.37 on Revenues of $91.54M
-
Ultragenyx Pharma (RARE) Tops Q3 EPS by 14c, Revenues Beat
-
Ultragenyx Pharma (RARE) Tops Q2 EPS by $1.95, Revenue Beat; Offers FY20 Crysvita Outlook
-
Ultragenyx Pharma (RARE) Misses Q1 EPS by 36c
-
Ultragenyx Pharma (RARE) Tops Q4 EPS by 3c, Revenues Beat
-
Ultragenyx Pharma (RARE) Misses Q3 EPS by 28c
-
Ultragenyx Pharma (RARE) Misses Q2 EPS by 2c, Revenues Beat
-
Ultragenyx Pharma (RARE) Misses Q1 EPS by 8c
-
Ultragenyx Pharma (RARE) Tops Q4 EPS by 6c, Revenues Beat
-
Ultragenyx Pharma (RARE) Tops Q3 EPS by 22c, Revenues Beat
-
Ultragenyx Pharma (RARE) phase 3 study of UX007 in patients with Glut1 DS did not achieve its primary endpoint
-
Ultragenyx Pharma (RARE) Posts Smaller-than-Expected Q2 Loss
-
Ultragenyx Pharma (RARE) Reports Q1 EPS of $0.62
-
Ultragenyx Pharma (RARE) Confirms FDA Approval of Crysvita for X–Linked Hypophosphatemia
-
Ultragenyx Pharma (RARE) Tops Q4 EPS by 10c
-
Ultragenyx Pharma (RARE) Misses Q3 EPS by 1c
-
Ultragenyx Pharma (RARE) Says FDA Accepts Burosumab BLA; Sets 04/17/18 PDUFA Date
-
Ultragenyx Pharma (RARE) Offers to Acqurie Dimension Therapeutics (DMTX) for $5.50/Share
-
Ultragenyx Pharma (RARE) Phase 3 Study of Ace-ER in GNE Myopathy Doesn't Achieve Primary Endpoint
-
Ultragenyx Pharma (RARE) Tops Q2 EPS by 1c
-
Ultragenyx Pharma (RARE) Tops Q1 EPS by 8c
-
Ultragenyx (RARE), Kyowa Hakko Kirin and Kyowa Kirin Announce Positive 24-Week Data from Adult Phase 3 Study of Burosumab
-
UPDATE: Ultragenyx (RARE) Phase 2 UX007 Study Fails to Meet Primary Endpoint
-
Ultragenyx Pharma (RARE) Misses Q4 EPS by 3c
-
Ultragenyx Pharma (RARE) Misses Q3 EPS by 11c
-
Ultragenyx Pharma (RARE) Misses Q2 EPS by 2c
-
Ultragenyx Pharma (RARE) Misses Q1 EPS by 6c
-
Ultragenyx Pharma (RARE) Misses Q4 EPS by 28c
-
Ultragenyx Pharma (RARE) Misses Q3 EPS by 16c
-
Ultragenyx Pharma (RARE) Misses Q2 EPS by 20c
-
Ultragenyx Pharma (RARE) Tops Q4 EPS by 1c
-
Ultragenyx Pharmaceutical (RARE) Misses Q3 EPS by 4c
-
Ultragenyx Pharmaceutical Inc. (RARE) Misses Q2 EPS by 3c
-
Ultragenyx Pharmaceutical Inc. (RARE) Posts Q1 Loss of 85c/Share
-
Ultragenyx Pharmaceutical (RARE) IPO More than Doubles
Back to RARE Stock Lookup